Drug Trial Radar · NCT05415410
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
31
Actual
Start
May 25, 2022
Primary completion
Dec 17, 2024
Study completion Dec 17, 2024
Sponsor
- Lead sponsor
- VectivBio AGIndustry
- Sponsor type
- Industry
- First posted
- Jun 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal aGVHD.
Conditions
- GVHD
Interventions
ApraglutideDrug
Apraglutide is a new, synthetic glucagon-like peptide 2 (GLP-2) receptor agonist which acts as a gut targeted regenerative approach that is intestinotrophic with a mode of action that improves absorption and enhances gut barrier function.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Screening (up to 12 weeks) through End of Trial (up to 2 years/104 weeks) for a total of up to 116 weeks
- Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESIs)Time frame: From first dose of study drug through End of Trial (up to 2 years/104 weeks) for a total of up to 116 weeks
- Number of Participants With Clinically Significant Changes From Baseline Over Time in Vital SignsTime frame: Baseline, Weeks 1, 2, 3, 4, 6, 8, 13, 17, 21, 26, 52, End of Treatment (up to Week 25), Week 104/End of Trial
- Number of Participants With Clinically Significant Changes From Baseline Over Time in QT Corrected for Heart Rate Using Fridericia's Formula (QTcF)Time frame: Baseline, Weeks 26, 52, 104/End of Trial
- Number of Participants With Potentially Clinically Significant Values Over Time in Liver Function Tests: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)Time frame: Baseline, Weeks 1, 2, 3, 4, 6, 8, 13, 17, 21, 26, 52, End of Treatment (up to Week 25), Week 104/End of Trial
- Number of Participants With Potentially Clinically Significant Values Over Time in Liver Function Tests: Total BilirubinTime frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 52, End of Treatment (up to Week 25), Week 104/End of Trial
- Number of Participants With Potentially Clinically Significant Values Over Time in Liver Function Tests: Potential Hy's Law CasesTime frame: Baseline, Weeks 1, 2, 3, 4, 6, 8, 13, 17, 21, 26, 52, End of Treatment (up to Week 25), Week 104/End of Trial
- Number of Participants With Anti-drug Antibodies (ADAs) Over TimeTime frame: Baseline, Weeks 1, 2, 3, 4, 6, 8, 13, 17, 21, 26, 52, End of Treatment (up to Week 25), Week 104/End of Trial
- Shift Table From Baseline to Worst Post-Treatment (WPT) Physical ExaminationsTime frame: Baseline (BL), up to Week 104/End of Treatment
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
Stanford Cancer Center
Stanford, California
University of Iowa
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
The Ohio State University
Columbus, Ohio
South Austin Medical Center
Austin, Texas
Universitätsklinikum Köln (AoeR)
Cologne, Germany
Universitaetsklinikum Duesseldorf
Düsseldorf, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Martin Luther Universität Halle-Wittenberg
Halle, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Universitätsmedizin der Johannes Gutenberg - Universität Mainz
Mainz, Germany
Instituto Portugues de Oncologia do Porto Francisco Gentil
Porto, Portugal
Hospital Universitario Virgen del Rocio
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.